Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma.
| Authors | Michael Wang, Simon Rule, Pier Luigi Zinzani, Andre Goy, Olivier Casasnovas, Stephen D Smith, Gandhi Damaj, Jeanette K Doorduijn, Thierry Lamy, Franck Morschhauser, Carlos Panizo, Bijal Shah, Andrew Davies, Richard Eek, Jehan Dupuis, Eric Jacobsen, Arnon P Kater, Steven Le Gouill, Lucie Oberic, Tadeusz Robak, Preetesh Jain, Melanie M Frigault, Raquel Izumi, Dorothy Nguyen, Priti Patel, Ming Yin, Monika Długosz-Danecka |
| Journal | Leukemia
(Leukemia)
Vol. 33
Issue 11
Pg. 2762-2766
(11 2019)
ISSN: 1476-5551 [Electronic] England |
| PMID | 31558766
(Publication Type: Clinical Trial, Phase II, Letter, Multicenter Study, Research Support, Non-U.S. Gov't)
|
| Chemical References |
- Antineoplastic Agents
- Benzamides
- Ki-67 Antigen
- Pyrazines
- Agammaglobulinaemia Tyrosine Kinase
- BTK protein, human
- acalabrutinib
|
| Topics |
- Adult
- Agammaglobulinaemia Tyrosine Kinase
(antagonists & inhibitors)
- Aged
- Aged, 80 and over
- Antineoplastic Agents
(therapeutic use)
- Benzamides
(therapeutic use)
- Cell Proliferation
- Disease Progression
- Drug Resistance, Neoplasm
- Female
- Follow-Up Studies
- Humans
- Ki-67 Antigen
(metabolism)
- Lymphoma, Mantle-Cell
(drug therapy)
- Male
- Middle Aged
- Neoplasm Recurrence, Local
(drug therapy)
- Neoplasm, Residual
- Pyrazines
(therapeutic use)
- Time Factors
- Treatment Outcome
|
|
Join CureHunter, for free Research Interface BASIC access!
Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease.
Find out why thousands of doctors, pharma researchers and patient activists
around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!
|
